Mariano R Gabri Selected Research

CMPacetylneuraminate monooxygenase (CMP-N-acetylneuraminate monooxygenase)

7/2012	Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides.
12/2009	Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mariano R Gabri Research Topics

Disease

23	Neoplasms (Cancer) 12/2020 - 03/2002
9	Melanoma (Melanoma, Malignant) 07/2012 - 03/2002
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2018 - 12/2007
4	Neoplasm Metastasis (Metastasis) 05/2018 - 03/2002
4	Neuroblastoma 01/2016 - 03/2010
3	Retinoblastoma (Glioblastoma, Retinal) 12/2016 - 03/2010
3	Lung Neoplasms (Lung Cancer) 01/2016 - 01/2010
3	Experimental Melanoma 07/2012 - 12/2002
2	Breast Neoplasms (Breast Cancer) 01/2011 - 01/2010
2	Carcinoma (Carcinomatosis) 12/2009 - 02/2007
1	Glioma (Gliomas) 12/2020
1	Lung Diseases (Lung Disease) 01/2012
1	Lewis Lung Carcinoma 01/2012
1	Neuroectodermal Tumors (Neuroectodermal Tumor) 01/2011
1	Meningococcal Meningitis 02/2010
1	Wilms Tumor (Wilm's Tumor) 01/2010
1	Disease Progression 05/2008
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2007
1	Hypersensitivity (Allergy) 12/2006
1	Residual Neoplasm 12/2006

Drug/Important Bio-Agent (IBA)

16	GangliosidesIBA 08/2018 - 03/2002
14	VaccinesIBA 05/2018 - 03/2002
6	AntigensIBA 08/2018 - 03/2002
6	racotumomabIBA 08/2018 - 01/2010
6	Monoclonal AntibodiesIBA 08/2018 - 03/2002
6	Messenger RNA (mRNA)IBA 12/2016 - 05/2008
5	EnzymesIBA 09/2018 - 03/2002
4	G(M3) GangliosideIBA 05/2018 - 12/2002
3	AntibodiesIBA 08/2018 - 02/2007
3	Sulfoglycosphingolipids (Sulfatides)IBA 01/2012 - 02/2007
2	Polysaccharides (Glycans)IBA 12/2020 - 09/2018
2	Transcription Factors (Transcription Factor)IBA 12/2016 - 07/2015
2	aluminum sulfate (alum)IBA 01/2016 - 01/2012
2	CMPacetylneuraminate monooxygenase (CMP-N-acetylneuraminate monooxygenase)IBA 07/2012 - 12/2009
2	Neoplasm Antigens (Tumor Antigens)IBA 07/2012 - 01/2012
2	Cancer VaccinesIBA 07/2012 - 03/2002
2	GlycolipidsIBA 01/2012 - 03/2002
2	Aluminum Hydroxide (Algeldrate)FDA Link 01/2012 - 01/2012
2	N-glycolylneuraminyllactosylceramide (HD3)IBA 01/2011 - 01/2010
2	Formaldehyde (Formol)FDA Link 01/2011 - 01/2010
2	ParaffinIBA 01/2011 - 01/2010
1	SwainsonineIBA 12/2020
1	trichostatin A (A 300)IBA 12/2020
1	FucosyltransferasesIBA 12/2020
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2020
1	TunicamycinIBA 12/2020
1	GlycosyltransferasesIBA 12/2020
1	IntegrinsIBA 05/2018
1	Immunoglobulin G (IgG)IBA 01/2016
1	GlycoconjugatesIBA 01/2016
1	N-glycolylneuraminic acidIBA 07/2012
1	CytidineIBA 07/2012
1	Pemetrexed (MTA)FDA Link 01/2012
1	Biological ProductsIBA 01/2012
1	GD2 gangliosideIBA 03/2010
1	(N- acetylneuraminyl)- galactosylglucosylceramide N-acetylgalactosaminyltransferaseIBA 03/2010
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2010
1	MucinsIBA 12/2009
1	Monophenol Monooxygenase (Tyrosinase)IBA 05/2008
1	RNA (Ribonucleic Acid)IBA 05/2008
1	CytokinesIBA 12/2006
1	montanide ISA 51IBA 11/2004
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 12/2002

Therapy/Procedure

8	Immunotherapy 01/2016 - 11/2004
4	Therapeutics 05/2018 - 03/2002
3	Drug Therapy (Chemotherapy) 08/2018 - 01/2012
1	Aftercare (After-Treatment) 12/2020
1	Radiotherapy 01/2016
1	Induction Chemotherapy 07/2015